10/11/2026
A PharmD candidate. A neuroscience PhD student. A pharmaceutical sciences PhD student. Three different disciplines, one published paper.
Congratulations to Dr. Jianxiong Jiang and his team on the publication of a new mini-review in Trends in Pharmacological Sciences, a leading journal in the field of pharmacology.
The manuscript, "Centanafadine (Simtriyo): a triple monoamine reuptake inhibitor for ADHD," was developed through the combined efforts of graduate and professional students, each contributing a distinct area of expertise:
Alyssia Antwania Pruitt, PharmD Candidate, Class of 2028, compiled the timeline of the drug's development, clinical use, and adverse effects.
Juqian (Amy) Han, Biomedical Sciences (Neuroscience Track), contributed expertise in monoamine neurotransmission and signaling.
Chenyao (Jacob) Jiang, PhD student in Pharmaceutical Sciences, provided medicinal chemistry perspectives and the drug's pharmacokinetic/pharmacodynamic profile.
Together, this team produced a timely and rigorous review of centanafadine, a newly FDA-approved, first-in-class therapy for ADHD in both adult and pediatric patients, and a strong example of how interdisciplinary collaboration between trainees from pharmacy practice, pharmaceutical sciences, and neuroscience can combine their respective strengths to produce scholarship suitable for publication in a high-impact journal.
Collaboration, research, and innovation go hand in hand at the UT Health Science Center College of Pharmacy, reflecting the opportunities for Pharmaceutical Sciences and PharmD students to contribute directly to peer-reviewed scholarship alongside PhD researchers from different disciplines and faculty, well before graduation.
Please join us in congratulating the entire team on this accomplishment.
Read the full article: https://bit.ly/4jO6Bgv